TRA2A

Across TCGA pan-cancer cohorts, TRA2A mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TRA2A data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher TRA2A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TRA2A expression acts as an unfavorable survival marker, although some lineages such as LSCC and COAD show a favorable association.

LSCC, HNSC, and COAD are the cancer types where TRA2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.882	0.541	.001	42	view →
HNSC	OS	Quartile	All	0.176	0.973	.017	27	view →
COAD	DFS	Tertile	III,IV	1.000	0.773	.036	12	view →
UCEC	DFS	Tertile	III,IV	0.328	1.000	.022	8	view →
PDAC	DFS	Median	All	0.814	0.709	.009	8	view →
GBM	DFS	Quartile	All	0.425	0.191	.041	2	view →
CCRCC	DFS	Tertile	III,IV	0.806	1.000	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TRA2A–LSCC (DFS)

Open the LSCC breakdown →